文献速递皮肤肿瘤

手术切除与5%5-氟尿嘧啶及光动力疗法治疗Bowen病的长期随机对照试验结果

Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: Long-term results of a multicenter randomized controlled trial.
PubMed 文献 · J Am Acad Dermatol · 2025-12-12

这项多中心非劣效随机对照试验纳入250例Bowen病患者,比较5-氟尿嘧啶(5FU)、甲基氨基酮戊酸光动力疗法(MAL-PDT)与手术切除(SE)的长期疗效。4年无瘤生存累积概率SE为97.5%,5FU为86.2%,MAL-PDT为82.7%;5FU仍非劣于SE,而MAL-PDT的非劣效性未能确立。

要点

  • 5FU在4年无瘤生存上仍非劣于手术切除。
  • MAL-PDT未能确立相对于手术切除的非劣效性。
  • 治疗后区域未观察到皮肤鳞状细胞癌发生。

核心结论

  • 长期随访中,5FU和SE治疗后Bowen病额外复发风险及治疗区域发生cSCC的风险可忽略。
  • 5FU仍非劣于SE,而MAL-PDT的非劣效性未能得出结论。

研究设计与样本

  • 多中心、非劣效随机对照试验,250例Bowen病患者按1:1:1随机分配至5FU、MAL-PDT或SE组。
  • 邀请患者于治疗后3至5年进行长期随访。

主要发现

  • 随访第一年观察到27例治疗失败;长期随访中仅1例在MAL-PDT后5年出现额外复发。
  • 4年无瘤生存累积概率:SE为97.5%(95%CI 90.4-99.4),5FU为86.2%(95%CI 76.4-92.1),MAL-PDT为82.7%(95%CI 72.6-89.4)。
  • 无患者在治疗区域发生皮肤鳞状细胞癌(cSCC)。

关键数值与推荐

  • 主要结局为治疗后4年无瘤生存累积概率,治疗失败经组织病理学确认。
  • 次要终点为皮肤鳞状细胞癌(cSCC)风险。

临床怎么用

  • 对于Bowen病,5FU可作为手术切除的非劣效替代选择。
  • MAL-PDT长期疗效未证实非劣于手术切除,选择时需权衡。

局限性

  • 23.2%的患者失访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence on long-term efficacy with head-to-head comparison of different treatments for Bowen's disease (BD) is lacking. OBJECTIVE: To compare the long-term efficacy of 5-fluorouracil and methylaminolevulinate photodynamic therapy (MAL-PDT) versus surgical excision (SE) in BD. METHODS: In this multicenter, non-inferiority randomized controlled trial, 250 patients with BD were invited for long-term follow-up, 3 to 5 years post-treatment. Patients had been randomly assigned to 5FU, MAL-PDT, or SE in a 1:1:1-ratio. The primary outcome was the cumulative probability of tumor-free survival 4 years post-treatment with treatment failures confirmed histopathologically. A secondary endpoint was the risk of cutaneous squamous cell carcinoma (cSCC). RESULTS: During the first year of follow-up, treatment failure was observed in 27 patients. During long-term follow-up, only 1 additional patient developed a recurrence, 5 years after MAL-PDT. The 4-year cumulative probability of tumor-free survival was 97.5% for SE (95% confidence interval (CI) 90.4-99.4), 86.2% for 5FU (95% CI 76.4-92.1), and 82.7% for MAL-PDT (95% CI 72.6-89.4). No patient developed a cSCC in the treated area. LIMITATIONS: Loss to follow-up occurred in 23.2% of patients. CONCLUSIONS: During long-term follow-up, the additional risk of recurrence of BD after 5FU and SE, and the risk of developing a cSCC from a treated BD were negligible. Treatment with 5FU remains non-inferior to SE, whereas non-inferiority of MAL-PDT could not be concluded.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Moermans MMG, Ahmady S, Nelemans PJ, et al. Surgical excision versus topical 5% 5-fluorouracil and photodynamic therapy in the treatment of Bowen's disease: Long-term results of a multicenter randomized controlled trial. J Am Acad Dermatol. 2025. PMID: 41391634. doi:10.1016/j.jaad.2025.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。